The reduction in price target by Mizuho reflects a negative outlook on ACADIA Pharmaceuticals' stock price in the short term. A lower price target, especially when maintained by a neutral stance, suggests that the analyst sees limited upside potential and possible downside risks. This could lead to a negative perception among investors, potentially impacting the stock price negatively in the short term.